153 related articles for article (PubMed ID: 2785852)
1. Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.
Yamasaki K; Sone S; Yamashita T; Ogura T
Cancer Immunol Immunother; 1989; 29(2):87-92. PubMed ID: 2785852
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
[TBL] [Abstract][Full Text] [Related]
3. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
4. [Study on the enhancing effect of polyporus polysaccharide, mycobacterium polysaccharide and lentinan on lymphokine-activated killer cell activity in vitro].
Li JF; Guo JW; Huang XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Apr; 16(4):224-6. PubMed ID: 9206247
[TBL] [Abstract][Full Text] [Related]
5. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of lymphokine-activated killer cell activity by lentinan.
Tani M; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Noguchi K; Tamai M; Hotta T; Mizobata S
Anticancer Res; 1993; 13(5C):1773-6. PubMed ID: 8267381
[TBL] [Abstract][Full Text] [Related]
7. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
9. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
12. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
Mulé JJ; Shu S; Schwarz SL; Rosenberg SA
Science; 1984 Sep; 225(4669):1487-9. PubMed ID: 6332379
[TBL] [Abstract][Full Text] [Related]
14. [Effects of six polysaccharides extracted from plants on the immunological cells of mice].
Wang G; Lin W; Zhao R; Lin N
Wei Sheng Yan Jiu; 2008 Sep; 37(5):577-80. PubMed ID: 19069658
[TBL] [Abstract][Full Text] [Related]
15. Acting mechanisms of Lentinan in human--II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon inducer.
Miyakoshi H; Aoki T; Mizukoshi M
Int J Immunopharmacol; 1984; 6(4):373-9. PubMed ID: 6207124
[TBL] [Abstract][Full Text] [Related]
16. The effect of lentinan on production of interleukin-1 by human monocytes.
Fruehauf JP; Bonnard GD; Herberman RB
Immunopharmacology; 1982 Oct; 5(1):65-74. PubMed ID: 6982258
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
18. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
19. Induction of endogenous lymphokine-activated killer activity by combined administration of lentinan and interleukin 2.
Suzuki M; Higuchi S; Taki Y; Taki S; Miwa K; Hamuro J
Int J Immunopharmacol; 1990; 12(6):613-23. PubMed ID: 2272726
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of antitumor effect of recombinant interleukin-2 activated killer cells by the administration of rIL-2 and lentinan.
Shimizu H; Inoue M; Shimizu C; Saito J; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1899-900. PubMed ID: 3264845
[No Abstract] [Full Text] [Related]
[Next] [New Search]